title: Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
authors.forename: Alessandro
authors.initials: A
authors.lastname: Morabito
authors.forename: Maria Carmela
authors.initials: MC
authors.lastname: Piccirillo
authors.forename: Ermelinda
authors.initials: E
authors.lastname: De Maio
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D012307:Risk Factors; D018401:Sample Size; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab